



BERYL DRUGS LIMITED
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) - 462 001.
Tel./ Fax 0731-3961510
E-mail : beryldrugs25@yahoo.com

ANNEXURE I


Part I Submission of Unaudited/ Audited Financial Result by Companies Other than Banks			
Statement of standalone / Consolidated / Audited Result for the Quarter/ year ended 30/06/2017			
(Rs in 000)			
Particulars		3 months ended (30-06-2017)	Corresponding 3 months ended in the previous year (30-06-2016)
		Unaudited	Unaudited
(Refer Notes Below)			
1	Revenue From Operations		
	Net sales or Revenue from Operations		
	Other operating revenues	48470.000	30400.000
		378.000	561.000
2	Expenses		
	Total Revenue from operations (net)	48848.000	30961.000
(a)	Cost of materials consumed		
(b)	Purchases of stock-in-trade	26012.000	23292.000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.000	0.000
(d)	Employee benefit expense	10905.000	504.000
(e)	Finance costs	1655.000	2596.000
(f)	Depreciation and amortisation expense	373.000	536.000
(g)	Other Expenses	1000.000	1000.000
		7616.000	1610.000
3			
	Total expenses	47561.000	29538.000
4	Exceptional items		
	Profit (loss) from operations before exceptional and extraordinary items and tax	1287.000	1423.000
5			
	profit (loss) before extraordinary items and tax	0.000	0.000
6	Extraordinary items		
	profit (loss) before tax	1287.000	1423.000
7			
	Profit (loss) before tax	0.000	0.000
8	Tax Expense		
	Current tax		
	Deferred tax	320.000	200.000
		0.000	0.000
	Total Tax Expenses	320.000	200.000
9	Net Profit (loss) for the period from continuing operations	967.000	1223.000
10	Net Profit (loss) from discontinuing operations before tax		
11	Tax Expense of discontinuing operations	0.000	0.000
12	Net Profit (loss) from discontinuing operations after tax	0.000	0.000
13		0.000	0.000
	Net Profit (loss) for the Period	967.000	1223.000
14	Details of equity share capital		
	Paid-up equity share capital		
	Face value of equity share capital	50717.000	50717.000
15	Earnings per share		
i	Basic earnings per share before extraordinary items	10.000	10.000
ii	Diluted earnings per share before extraordinary items	0.191	0.241
		0.191	0.241

Notes

- The Quarterly results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 07th July 2017. The Statutory Auditors have carried out a limited review of the results for the quarter ended June 30, 2017.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) PRESCRIBED UNDER SECTION 133 OF THE Companies Act, 2013, & other recognized accounting practices & policies to the extent applicable.
- The Income from Operations is from one segment namely "Pharmaceutical Industry".
- Previous period exp. have been regrouped / rearranged, wherever necessary.
- Taxes and depreciation are calculated on proportionate basis on annual estimated basis.
- The Ind AS compliant financial results, Pertaining to period ended June 30, 2016 have not been subject to limited review or audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- Reconciliation of Profit reported in accordance with previous Indian GAAP (IGAAP) to total comprehensive Income in accordance with Ind AS is given below:

Particulars	Corresponding 3 months ended in the previous year June 30, 2016 (Rs in 000)
Profit for the period as per I GAAP	
Amortization of Goodwill	1223.000
Reclassification of net actuarial loss on defined obligation to other comprehensive income	0
Charge of group ESCOP	0
Tax impact in Ind AS adjustment	0
Other comprehensive income as per Ind AS	0
Total Comprehensive Income as per Ind AS	1223.000

Place Indore
Date 07.07.2017



SUBHASH CHAND JAIN ANURAG & ASSOCIATES
CHARTERED ACCOUNTANTS

4, Archana Apartment,
8-B, Ratlam Kothi, Indore - 452 001 (M.P.)
Ph: 2519439, 2527682
Mob No: 93021-23882
Email: scjainca2004@yahoo.com



LIMITED REVIEW REPORT

To
The Board of Directors
Beryl Drugs Limited
133, Kanchan Bagh, Indore (M.P.)

We have reviewed the accompanying statement of unaudited financial results of **BERYL DRUGS LIMITED** for the period ended **30/06/2017**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR- SUBHASH CHAND JAIN ANURAG & ASSOCIATES
CHARTERED ACCOUNTANTS
FRN-004733C



Date: 06/07/2017
Place: Indore

(BADAL BANGUR)
PARTNER
M. No. 423724